We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Bioanalysis
BioTechniques
Future Drug Discovery
Future Medicinal Chemistry
Future Science OA
International Journal of Pharmacokinetics
Pharmaceutical Patent Analyst
Therapeutic Delivery
Review

Mycobacterium tuberculosis topoisomerases and EthR as the targets for new anti-TB drugs development

    Rafal Sawicki

    *Author for correspondence: Tel.: +48 606 312 059;

    E-mail Address: rafal.sawicki@umlub.pl

    Department of Biochemistry & Biotechnology, Medical University of Lublin, Chair, Chodzki 1, PL-20093 Lublin, Poland

    Search for more papers by this author

    &
    Grazyna Ginalska

    Department of Biochemistry & Biotechnology, Medical University of Lublin, Chair, Chodzki 1, PL-20093 Lublin, Poland

    Search for more papers by this author

    Published Online:20 Sep 2019https://doi.org/10.4155/fmc-2018-0232

    Abstract

    The significant increase in the detection of drug-resistant strains of Mycobacterium tuberculosis caused an urgent need for the discovery new antituberculosis drugs. Development of bioinformatics and computational sciences enabled the progress of new strategies leading to design, discovery and identification of a series of interesting drug candidates. In this short review, we would like to present recently discovered compounds targeting important mycobacterial proteins: DNA topoisomerases and the transcriptional repressor of EthA monooxygenase – EthR.

    Papers of special note have been highlighted as: • of interest; •• of considerable interest

    References

    • 1. WHO. Guidelines for the programmatic management of drug-resistant tuberculosis (2011). https://apps.who.int/iris/bitstream/handle/10665/44597/9789241501583_eng.pdfGoogle Scholar
    • 2. WHO. Guidelines for treatment of drug-susceptible tuberculosis and patient care. Essential First-line antituberculosis drugs. Annex 6 (2017). https://www.who.int/tb/publications/2017/tb_guidelines2017_annex6_en_v4.pdfGoogle Scholar
    • 3. Champoux JJ. DNA topoisomerases: structure, function, and mechanism. Annu. Rev. Biochem. 70, 369–413 (2001).Crossref, Medline, CAS, Google Scholar
    • 4. Tse-Dinh YC. Targeting bacterial topoisomerase I to meet the challenge of finding new antibiotics. Fut. Med. Chem. 7(4), 459–471 (2015).Link, CAS, Google Scholar
    • 5. Ravishankar S, Ambady A, Awasthy D et al. Genetic and chemical validation identifies Mycobacterium tuberculosis topoisomerase I as an attractive anti-tubercular target. Tuberculosis 95(5), 589–598 (2015).Crossref, Medline, CAS, Google Scholar
    • 6. Stockum A, Lloyd RG, Rudolph CJ. On the viability of Escherichia coli cells lacking DNA topoisomerase I. Bmc Microbiol. 12, 26 (2012).Crossref, Medline, CAS, Google Scholar
    • 7. Sandhaus S, Chapagain PP, Tse-Dinh Y-C. Discovery of novel bacterial topoisomerase I inhibitors by use of in silico docking and in vitro assays. Sci. Rep. 8(1), 1437 (2018). • The new fluoroquinolones were tested against one fluoroquinolone-sensitive and nine fluoroquinolone-resistant clinical isolates of Mycobacterium tuberculosis.Crossref, Medline, Google Scholar
    • 8. Schoeffler AJ, Berger JM. DNA topoisomerases: harnessing and constraining energy to govern chromosome topology. Q. Rev. Biophys. 41(1), 41–101 (2008).Crossref, Medline, CAS, Google Scholar
    • 9. Tretter EM, Berger JM. Mechanisms for defining supercoiling set point of DNA gyrase orthologs II-the shape of the gyra subunit c-terminal domain (Ctd) is not a sole determinant for controlling supercoiling efficiency. J. Biol. Chem. 287(22), 18645–18654 (2012).Crossref, Medline, CAS, Google Scholar
    • 10. Tan K, Cao N, Cheng B, Joachimiak A, Tse-Dinh Y-C. Insights from the structure of Mycobacterium tuberculosis Topoisomerase I with a novel protein fold. J. Mol. Biol. 428(1), 182–193 (2016).Crossref, Medline, CAS, Google Scholar
    • 11. Godbole AA, Ahmed W, Bhat RS, Bradley EK, Ekins S, Nagaraja V. Targeting Mycobacterium tuberculosis Topoisomerase I by small-molecule inhibitors. Antimicrob. Agents Chemother. 59(3), 1549–1557 (2015).Crossref, Medline, Google Scholar
    • 12. Temesszentandrasi-Ambrus C, Toth S, Verma R et al. Characterization of new, efficient Mycobacterium tuberculosis topoisomerase-I inhibitors and their interaction with human ABC multidrug transporters. PLoS ONE 13(9), e0202749 (2018). • Describes new class of quinolones proofed to be efficacious in various murine models of tuberculosis.Crossref, Medline, Google Scholar
    • 13. Shi R, Zhang J, Li C, Kazumi Y, Sugawara I. Emergence of ofloxacin resistance in Mycobacterium tuberculosis clinical isolates from China as determined by gyrA mutation analysis using denaturing high-pressure liquid chromatography and DNA sequencing. J. Clin. Microbiol. 44(12), 4566–4568 (2006).Crossref, Medline, CAS, Google Scholar
    • 14. Guerrini V, De Rosa M, Pasquini S et al. New fluoroquinolones active against fluoroquinolones-resistant Mycobacterium tuberculosis strains. Tuberculosis (Edinb.) 93(4), 405–411 (2013). • Presents a new powerful series of M. tuberculosis gyrase inhibitors tested in an acute mycobacterial infection murine model.Crossref, Medline, CAS, Google Scholar
    • 15. Agrawal KM, Talele GS. Synthesis and antibacterial, antimycobacterial and docking studies of novel N-piperazinyl fluoroquinolones. Med. Chem. Res. 22(2), 818–831 (2013).Crossref, CAS, Google Scholar
    • 16. Charifson PS, Grillot AL, Grossman TH et al. Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: Intelligent design and evolution through the judicious use of structure-guided design and stucture-activity relationships. J. Med. Chem. 51(17), 5243–5263 (2008).Crossref, Medline, CAS, Google Scholar
    • 17. Manchester JI, Dussault DD, Rose JA et al. Discovery of a novel azaindole class of antibacterial agents targeting the ATPase domains of DNA gyrase and Topoisomerase IV. Bioorg. Med. Chem. Lett. 22(15), 5150–5156 (2012).Crossref, Medline, CAS, Google Scholar
    • 18. East SP, White CB, Barker O et al. DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: Synthesis and antibacterial activity (vol 19, pg 894, 2009). Bioorg. Med. Chem. Lett. 19(9), 2606–2606 (2009).Crossref, CAS, Google Scholar
    • 19. Hameed PS, Patil V, Solapure S et al. Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis. J. Med. Chem. 57(11), 4889–4905 (2014).Crossref, Medline, Google Scholar
    • 20. Bobesh KA, Renuka J, Jeankumar VU et al. Extending the N-linked aminopiperidine class to the mycobacterial gyrase domain: pharmacophore mapping from known antibacterial leads. Eur. J. Med. Chem. 85, 593–604 (2014).Crossref, Medline, CAS, Google Scholar
    • 21. Blanco D, Perez-Herran E, Cacho M et al. Mycobacterium tuberculosis gyrase inhibitors as a new class of antitubercular drugs. Antimicrob. Agents Chemother. 59(4), 1868–1875 (2015).Crossref, Medline, CAS, Google Scholar
    • 22. Gibson EG, Blower TR, Cacho M, Bax B, Berger JM, Osheroff N. Mechanism of action of Mycobacterium tuberculosis gyrase inhibitors: a novel class of gyrase poisons. 4(8), 1211–1222 (2018).Crossref, Google Scholar
    • 23. Renuka J, Reddy KI, Srihari K et al. Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis. Bioorg. Med. Chem. 22(17), 4924–4934 (2014). • Describes the discovery of a new chemical family of EthR inhibitorsCrossref, Medline, CAS, Google Scholar
    • 24. Jeankumar VU, Renuka J, Santosh P et al. Thiazole-aminopiperidine hybrid analogues: design and synthesis of novel Mycobacterium tuberculosis GyrB inhibitors. Eur. J. Med. Chem. 70, 143–153 (2013).Crossref, Medline, CAS, Google Scholar
    • 25. McGarry DH, Cooper IR, Walker R et al. Design, synthesis and antibacterial properties of pyrimido[4,5-b]indol-8-amine inhibitors of DNA gyrase. 28(17), 2998–3003 (2018).Crossref, Google Scholar
    • 26. Salve PS, Alegaon SG. Synthesis of new 7-chloro-4-phenoxyquinoline analogues as potential antitubercular agents. Med. Chem. Res. 27(1), 1–14 (2018). •• The breakthrough article describing the discovery of alternative ethionamide bioactivation pathway.Crossref, CAS, Google Scholar
    • 27. Patel K, Tyagi C, Goyal S et al. Identification of chebulinic acid as potent natural inhibitor of M. tuberculosis DNA gyrase and molecular insights into its binding mode of action. Comput. Biol. Chem. 59(Pt A), 37–47 (2015).Crossref, Medline, CAS, Google Scholar
    • 28. Vannelli TA, Dykman A, Ortiz de Montellano PR. The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase. J. Biol. Chem. 277(15), 12824–12829 (2002).Crossref, Medline, CAS, Google Scholar
    • 29. Willand N, Dirie B, Carette X et al. Synthetic EthR inhibitors boost antituberculous activity of ethionamide. Nat. Med. 15(5), 537–544 (2009).Crossref, Medline, CAS, Google Scholar
    • 30. Flipo M, Willand N, Lecat-Guillet N et al. Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis. J. Med. Chem. 55(14), 6391–6402 (2012).Crossref, Medline, CAS, Google Scholar
    • 31. Villemagne B, Flipo M, Blondiaux N et al. Ligand efficiency driven design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approaches. J. Med. Chem. 57(11), 4876–4888 (2014).Crossref, Medline, CAS, Google Scholar
    • 32. DeBarber AE, Mdluli K, Bosman M, Bekker LG, Barry CE. Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 97(17), 9677–9682 (2000).Crossref, Medline, CAS, Google Scholar
    • 33. Brossier F. Mechanisms of action and resistance to INH, a first-line antituberculous drug. J. Antiinfect. 13(4), 217–227 (2011).CAS, Google Scholar
    • 34. Blondiaux N, Moune M, Desroses M et al. Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420. Science 355(6330), 1206–1211 (2017).Crossref, Medline, CAS, Google Scholar
    • 35. Organization WH. Global tuberculosis report 2018 (2018). http://apps.who.int/iris/bitstream/handle/10665/274453/9789241565646-eng.pdf?ua=1Google Scholar
    • 36. Walsh C. Antibiotics. American Society of Microbiology, Washington, DC, USA (2003).Crossref, Google Scholar